Clonical Dermatology. Developing a new treatment for acne based
on topical statins.
Employees: 4
Overview
LOVADERM LTD. is an emerging product-driven pharmaceutical
Click here to request more information, about this company (FOR COLLABORATION IN R&D. ONLY!)
Note - you have to be registered in this server to
request information. If you haven't done so
yet, please register in this server
Your requests will be forwarded to the developer, who
will contact you directly
You can also see the list of
documents you already requested more information about
company developing a novel therapeutic for acne based upon a
well-known active ingredient.
The pathogenesis of acne vulgaris is caused by the interplay of
the four factors responsible for the development of an acne
lesion.
* Follicular epidermal hyperproliferation.
* Excess sebum production.
* The presence and activity of Propionibacterium acnes.
* Inflammation.
The current topical therapeutics target three of the four
pathogenic factors associated with acne, leaving the primary
factor unresolved. At present, there is no topical therapy
directly affecting sebum production and thus, treatment of oily
skin and seborrhea remains an unmet need.
A successful proof-of-concept trial in humans assessed the
potential of Lovastatin as an anti-acne drug. In a double-blind
clinical study, Prof. Sarah Brenner (Head of Dermatology
Department, Tel Aviv Sourasky Medical Center) demonstrated the
effectiveness and safety of Lovastatin as a topical treatment for
acne vulgaris, with no apparent side effects.
The mechanism of action of statins in sebaceous glands is
well-known.
LOVADERM LTD. is currently seeking partnerships and strategic
collaborations in order to develop the product. These
collaborations will open up the possibility for both parties to
finance development with bi-national funds.
